US suitor wins Shire, and a British tax rate, in fifth takeover approach

The deal as it stands – £24.44 in cash and 0.896 AbbVie shares – would give Shire’s investors a 25 per cent stake in the combined company

Shire finally succumbed to US suitor AbbVie at the fifth time of asking yesterday as the drug group’s board said it was ready to recommend an improved $53bn (£31bn) takeover.

The FTSE 100 big-pharma player, best-known for its Vyvanse blockbuster treatment for attention deficit hyperactivity disorder, has been in the sights of AbbVie since early May when the US firm tabled its first bid proposal.

The two boards are now locked in “detailed discussions” in New York following the improved £53.20-a-share proposal, but AbbVie looks to have succeeded where US rival Pfizer failed in its much bigger £63bn bid for AstraZeneca. The deal as it stands – £24.44 in cash and 0.896 AbbVie shares – would give Shire’s investors a 25 per cent stake in the combined company. The shares rose 33p to 4,903p.

The company said: “The board of Shire has indicated to AbbVie that it would be willing to recommend an offer at the level of the revised proposal to Shire shareholders. Accordingly, the board is in detailed discussions with AbbVie in relation to these terms.”

The pursuit of Shire has stoked far less controversy than AstraZeneca because – apart from offices in Basingstoke – it is headquartered in Dublin but managed from Boston. The vast majority of Shire’s staff and sales are in the US.

AbbVie covets Shire’s rare diseases unit, bolstered by the $4.2bn deal for the US company ViroPharma last year, which the company is building up in response to more generic competitors to its ADHD drugs. It also wants Shire’s portfolio to reduce its reliance on its top-selling rheumatoid arthritis drug Humira, which accounts for 60 per cent of its sales but loses US patent protection in late 2016.

AbbVie is also looking to cut its US tax bill by moving its tax base to Britain, in a tactic known as inversion. Mick Cooper, an analyst at Edison Investment Research, said: “The proposed offer seems a fair price that represents good value for both companies’ shareholders.”

Shire previously fought to maintain its independence as its chairman Susan Kilsby unveiled a new target to double annual product sales, which account for the bulk of revenues, to $10bn by 2020.

The company was founded in 1986, with early successes including a range of calcium products to treat osteoporosis, and listed in 1996. The US firm was formed last year when Abbott Laboratories split into two companies, a medical products business which retained the Abbott name and a pharmaceuticals firm which became AbbVie.

Hooked: the string of deals

AbbVie’s £31bn takeover of Shire is the latest in a string  of huge deals – both successful and unsuccessful – in the sector this year:

April: Britain’s top drug maker, GlaxoSmithKline, reshuffles its drug cabinet with a three-part, multi-billion dollar asset swap with Swiss rival Novartis. It sells cancer drugs for Brentford-based Glaxo for up to $16bn, buying the Swiss giant’s vaccines operation for $5.25bn while the consumer health divisions of both are merged.

April-May: US firm Pfizer launches a takeover attempt for AstraZeneca – eventually raising its proposal to a potential $118bn or £55 a share – but the offer isn’t enough to bring Astra’s board to the table. Bad-tempered negotiations are conducted against a backdrop of political concerns over the impact of a deal on the UK’s research and development capacity.

April-July: Botox maker Allergan is still fending off a $53bn hostile approach from Canadian drug company Valeant and activist investor William Ackman.

Start your day with The Independent, sign up for daily news emails
ebooks
ebooksA special investigation by Andy McSmith
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Ashdown Group: Junior Application Support Analyst - Fluent German Speaker

£25000 - £30000 per annum + benefits: Ashdown Group: A global leader operating...

Recruitment Genius: Evening Administrator

£8 per hour: Recruitment Genius: This Pension Specialist was established early...

Guru Careers: Executive Assistant / PA

£30 - 35k + Bonus & Benefits: Guru Careers: We are seeking an Executive Assist...

Ashdown Group: Graduate Application Support Analyst

£25000 - £30000 per annum + benefits: Ashdown Group: A global leader operating...

Day In a Page

Homeless Veterans campaign: Donations hit record-breaking £1m target after £300,000 gift from Lloyds Bank

Homeless Veterans campaign

Donations hit record-breaking £1m target after huge gift from Lloyds Bank
Flight MH370 a year on: Lost without a trace – but the search goes on

Lost without a trace

But, a year on, the search continues for Flight MH370
Germany's spymasters left red-faced after thieves break into brand new secret service HQ and steal taps

Germany's spy HQ springs a leak

Thieves break into new €1.5bn complex... to steal taps
International Women's Day 2015: Celebrating the whirlwind wit of Simone de Beauvoir

Whirlwind wit of Simone de Beauvoir

Simone de Beauvoir's seminal feminist polemic, 'The Second Sex', has been published in short-form for International Women's Day
Mark Zuckerberg’s hiring policy might suit him – but it wouldn’t work for me

Mark Zuckerberg’s hiring policy might suit him – but it wouldn’t work for me

Why would I want to employ someone I’d be happy to have as my boss, asks Simon Kelner
Confessions of a planespotter: With three Britons under arrest in the UAE, the perils have never been more apparent

Confessions of a planespotter

With three Britons under arrest in the UAE, the perils have never been more apparent. Sam Masters explains the appeal
Russia's gulag museum 'makes no mention' of Stalin's atrocities

Russia's gulag museum

Ministry of Culture-run site 'makes no mention' of Stalin's atrocities
The big fresh food con: Alarming truth behind the chocolate muffin that won't decay

The big fresh food con

Joanna Blythman reveals the alarming truth behind the chocolate muffin that won't decay
Virginia Ironside was my landlady: What is it like to live with an agony aunt on call 24/7?

Virginia Ironside was my landlady

Tim Willis reveals what it's like to live with an agony aunt on call 24/7
Paris Fashion Week 2015: The wit and wisdom of Manish Arora's exercise in high camp

Paris Fashion Week 2015

The wit and wisdom of Manish Arora's exercise in high camp
8 best workout DVDs

8 best workout DVDs

If your 'New Year new you' regime hasn’t lasted beyond February, why not try working out from home?
Paul Scholes column: I don't believe Jonny Evans was spitting at Papiss Cissé. It was a reflex. But what the Newcastle striker did next was horrible

Paul Scholes column

I don't believe Evans was spitting at Cissé. It was a reflex. But what the Newcastle striker did next was horrible
Miguel Layun interview: From the Azteca to Vicarage Road with a million followers

From the Azteca to Vicarage Road with a million followers

Miguel Layun is a star in Mexico where he was criticised for leaving to join Watford. But he says he sees the bigger picture
Frank Warren column: Amir Khan ready to meet winner of Floyd Mayweather v Manny Pacquiao

Khan ready to meet winner of Mayweather v Pacquiao

The Bolton fighter is unlikely to take on Kell Brook with two superstar opponents on the horizon, says Frank Warren
War with Isis: Iraq's government fights to win back Tikrit from militants - but then what?

Baghdad fights to win back Tikrit from Isis – but then what?

Patrick Cockburn reports from Kirkuk on a conflict which sectarianism has made intractable